Mrna-Engineered Mesenchymal Stromal Cells Expressing CXCR2 Enhances Cell Migration and Improves Recovery in IBD

Qiaojia Li,Yufan Lian,Yiwen Deng,Jieying Chen,Tao Wu,Xinqiang Lai,Bowen Zheng,Chen Qiu,Yanwen Peng,Weiqiang Li,Andy Peng Xiang,Xiaoran Zhang,Jie Ren

DOI: https://doi.org/10.1016/j.omtn.2021.07.009

2021-01-01

Abstract:Mesenchymal stromal cells (MSCs) have shown significant heterogeneity in terms of therapeutic efficacy for inflammatory bowel disease (IBD) treatment, which may be due to an insufficient number of MSCs homing to the damaged tissue of the colon. Engineering MSCs with specific chemokine receptors can enhance the homing ability by lentiviral transduction. However, the unclear specific chemokine profile related to IBD and the safety concerns of viral-based gene delivery limit its application. Thus, a new strategy to modify MSCs to express specific chemokine receptors using mRNA engineering is developed to evaluate the homing ability of MSCs and its therapeutic effects for IBD. We found that CXCL2 and CXCL5 were highly expressed in the inflammatory colon, while MSCs minimally expressed the corresponding receptor CXCR2. Transient expression of CXCR2 in MSC was constructed and exhibited significantly enhanced migration to the inflamed colons, leading to a robust anti-inflammatory effect and high efficacy. Furthermore, the high expression of semaphorins7A on MSCs were found to induce the macrophages to produce IL-10, which may play a critical therapeutic role. This study demonstrated that the specific chemokine receptor CXCR2 mRNA-engineered MSCs not only improves the therapeutic efficacy of IBD but also provides an efficient and safe MSC modification strategy.